VivoSeq
Other

Prednisolone

0

Pipeline Programs

3

Active Trials

5

Companies Involved

Prednisolone is an early-stage landscape with 0 programs across 5 companies. The most active players are Novartis, Merck & Co., AstraZeneca.

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

90/100

Attrition Rate

6/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

32

clinical trials

Completed19 · 59%
Unknown status8 · 25%
Recruiting2 · 6%
Terminated1 · 3%
Active, not recruiting1 · 3%
Withdrawn1 · 3%

Trial Activity

32 trials

Loteprednol vs. Prednisolone and Fluorometholone
Completed·UUniversity of Utah·Phase 4·NCT03123614·131 enrolled
Prednisolone Trial in Children Younger Than 4 Years
Completed··Phase 3·NCT03141970·170 enrolled
Intravenous Immunoglobulin and Prednisolone for RPL After ART.
Completed··Phase 2·NCT04701034·80 enrolled
Biomarkers of Prednisolone Treatment (P05888)
Completed·Merck & Co. logoMerck & Co.·N/A·NCT00971724·72 enrolled
Comparison Between Symbicort® and Prednisolone in COPD
Completed·AstraZeneca logoAstraZeneca·Phase 3·NCT00259779·120 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)